Ignite Creation Date:
2024-05-06 @ 4:12 PM
Last Modification Date:
2024-10-26 @ 2:05 PM
Study NCT ID:
NCT04901117
Status:
UNKNOWN
Last Update Posted:
2021-05-25
First Post:
2021-05-24
Brief Title:
Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication A Randomized Clinical Trial of 10 and 14 Days
Sponsor:
Shandong University
Organization:
Shandong University
Study Overview
Official Title:
Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication A Multicenter Randomized Clinical Trial of 10 and 14 Days
Status:
UNKNOWN
Status Verified Date:
2021-05
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The researchers collect treatment-naive Hpylori-positive patients from the outpatient clinic The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy 6-8 weeks after treatment the subjects will re-take the 13C-urea breath test Calculate the eradication rates adverse reaction rates patient compliance and cost-effectiveness index of each group
Detailed Description:
The researchers collect treatment-naive Hpylori-positive patients from the outpatient clinic If the subject meets the selection criteria but not the exclusion criteria and signs an informed consent form the researchers randomized the subjects in groups subjects received a 10-day or 14-day course of bismuth-containing quadruple eradication therapy The medication of groups are as follows 6-8 weeks after the eradication treatment the subjects will review the 13C-urea breath test and the researcher records the results
After all subjects were tested the eradication rates adverse reaction rates patient compliance and cost-effectiveness index of each group were calculated
According to the course of treatment it is randomized into a 10-day treatment group and a 14-day treatment group The two groups of bismuth quadruple regimens are the same as follows
Option 1 Amoxicillin Clarithromycin Bismuth Vonoprazan fumarate Option 2 Amoxicillin Tetracycline Bismuth Vonoprazan fumarate Option 3 Amoxicillin Metronidazole Bismuth Vonoprazan fumarate Three options are selected according to the hospitals situation
After all subjects were tested the eradication rates adverse reaction rates patient compliance and cost-effectiveness index of each group were calculated
According to the course of treatment it is randomized into a 10-day treatment group and a 14-day treatment group The two groups of bismuth quadruple regimens are the same as follows
Option 1 Amoxicillin Clarithromycin Bismuth Vonoprazan fumarate Option 2 Amoxicillin Tetracycline Bismuth Vonoprazan fumarate Option 3 Amoxicillin Metronidazole Bismuth Vonoprazan fumarate Three options are selected according to the hospitals situation
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None